SEARCH

SEARCH BY CITATION

References

  • 1
    Fried MW, Shiffman ML, Rajender Reddy K, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 2
    Manns MP, McHutchinson JG, Gordon SC, et al. and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 95865.
  • 3
    Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacol 1988; 14: 3551.
  • 4
    Skehel JJ, Hay AJ, Armstrong JA . On the mechanism of inhibition of influenzae virus replication by amantadine hydrochloride. J Gen Virol 1978; 38: 97110.
  • 5
    Tabone M, Ercole E, Zaffino C, Sallio Bruno F, Pera A, Bonino F. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol 1998; 30: 6113.
  • 6
    Yagura M, Harada H. Treatment of chronic hepatitis C patients with amantadine. J Gastroenterol 2001; 36: 75963.
  • 7
    Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997; 42: 16817.
  • 8
    Cozzolongo R, Cuppone R, Manghisi OG. The treatment of chronic hepatitis C non responding to interferon. Curr Pharm Des 2002; 8: 96775.
  • 9
    Andant C, Lamoril J, Deybach JC, Jouet P, Soule JC. Amantadine for chronic hepatitis C: a pilot study in 14 patients. Eur J Gastroenterol Hepatol 2000; 12: 131922.
  • 10
    Senturk H, Mert A, Akdogan M, et al. Amantadine monotherapy of chronic hepatitis C in patients infected with genotype 1b. Scand J Infect Dis 2000; 32: 5756.
  • 11
    Zeuzem S, Teuber G, Naumann U, et al. Randomized, double-blind, placebo-controlled trial of interferon alfa-2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32: 83541.
  • 12
    Mangia A, Minerva A, Annese M, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001; 33: 98993.
  • 13
    Caronia S, Bassedine MF, Barry R, et al. Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study. J Hepatol 2001; 35: 51230.
  • 14
    Tabone M, Laudi C, Delmastro B, et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol 2001; 35: 52730.
  • 15
    Helbling B, Stamenic I, Viani F, et al. The Investigators of the Swiss Association for the Study of the Liver. Interferon and amantadine in naive chronic hepatitis C: a double-blind randomized, placebo-controlled trial. Hepatology 2002; 35: 44754.
  • 16
    Khailili M, Denhham C, Perrillo R. Interferon and ribavirin and amantadine in interferon non responders with chronic hepatitis C. Am J Gastroenterol 2000; 95: 12849.
    Direct Link:
  • 17
    Younossi ZM, Mullen KD, Zakko W, et al. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responders to interferon monotherapy. J Hepatol 2001; 34: 12833.
  • 18
    Gaeta GB, Stornaiuolo G, Stanzione M, et al. Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study. J Viral Hepat 2001; 8: 2846.
  • 19
    Teuber G, Berg T, Naumann U, et al. Randomized, placebo-controlled, double-blind trial with interferon-α with and without amantadine sulphate in primary interferon-α non responders with chronic hepatitis C. J Viral Hepat 2001; 8: 27683.
  • 20
    Bacosi M, Russo M, D'innocenzo S, et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatol Res 2002; 22: 2319.
  • 21
    Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32: 6304.
  • 22
    Zilly M, Lingenauber C, Desch S, Vath T, Kilinker H, Langmann P. Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in non responders to interferon-alpha and ribavirin. Eur J Med Res 2002; 7: 14954.
  • 23
    Carlsson T, Lindahl K, Schvarcz R , et al. HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin. J Viral Hepat 2000; 7: 40913.
  • 24
    Berg T, Naumann U, Wiedenmann B, Hopf U. Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Z Gastroenterol 2001; 39: 14551.
  • 25
    Di Marco V, Ferraro D, Almasio P, et al. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high dose interferon induction. J Viral Hepat 2002; 9: 3549.
  • 26
    Brouwer JT, Hansen BE, Niesters HG, Schalm SW. Early prediction of response in interferon monotherapy and in interferon–ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999; 30: 1928.
  • 27
    Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 6969.
  • 28
    Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999; 31(Suppl. 1): 5460.
  • 29
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with Peginterferon Alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 64552.